PENDING CLAIMS
[CLEAN COPY]

1. A protein comprising an immunoglobulin heavy chain (HC) variable domain and an immunoglobulin light chain (LC) variable domain, wherein the HC variable domain and the LC variable domain form an antigen binding site that binds to an activated conformation of LFA-1, wherein the protein has one or more of the following properties:

(i) the heavy chain variable domain comprises:

(a) a CDR1 that comprises RYVMW (SEQ ID NO: 1)

(b) a CDR2 that comprises YIWPSGGNTYYADSVKG (SEQ ID NO:2); and/or

(c) a CDR3 that comprises SYDFWSNAFDI (SEQ ID NO:3);

(ii) the light chain variable domain comprises

(a) a CDR1 that comprises RASQSIGSYLN (SEQ ID NO:7);

(b) a CDR2 that comprises AASSLQS (SEQ ID NO:8); and/or

(c) a CDR3 that comprises QQSYSTPS (SEQ ID NO:9);

(iii) the heavy chain variable domain comprises SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, or SEQ ID NO:29;

(iv) the light chain variable domain comprises SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, or SEQ ID NO:28;

(v) the heavy chain variable domain comprises a sequence encoded by a nucleic acid that hybridizes under high stringent conditions to a sequence that encodes the heavy chain variable domain of SEQ ID NO:42, SEQ ID NO:43, or SEQ ID NO:44;

(vi) the light chain variable domain comprises a sequence encoded by a nucleic acid that hybridizes under high stringent conditions to a sequence that encodes the light chain variable domain of SEQ ID NO: 42, SEQ ID NO:43, or SEQ ID NO:44; and/or

(vii) the protein which competes with an antibody selected from the group consisting of

SEQ ID NO:23, and an immunoglobulin light chain variable domain sequence comprising SEQ ID NO:22;

b) an immunoglobulin heavy chain variable domain sequence comprising SEQ ID NO:25, and an immunoglobulin light chain variable domain sequence comprising SEQ ID NO:24;

c) an immunoglobulin heavy chain variable domain sequence comprising SEQ ID NO:27, and an immunoglobulin light chain variable domain sequence comprising SEQ ID NO:26; and

d) an immunoglobulin heavy chain variable domain sequence comprising SEQ ID NO:29, and an immunoglobulin light chain variable domain sequence comprising SEQ ID NO:28;

for binding to activated LFA-1.

2. The protein of claim 1 that comprises at least the CDR regions of (i) and (ii).

3. The protein of claim 1 wherein the heavy and light chain variable domain sequences comprise, respectively, at least SEQ ID NO:23 and SEQ ID NO:22.

4. The protein of claim 1 wherein at least the protein framework regions are identical to SEQ ID NO:33 (heavy chain) and SEQ ID NO:36 (light chain); SEQ ID NO:34 (heavy chain) and SE ID NO:37 (light chain); or P1-G10.

5. The protein of claim 1 wherein the heavy chain variable domain comprises Xa-S-X2-D-X4-X5-S-X7-A-X8-X9-X10-X11 (SEQ ID NO:4), and

(i) Xa is S or N;

(ii) X2 is Y or F;

(iii) X4 is hydrophobic;

(iv) X5 is W or R;

(v) X7 is N or Y;

(vi) X9 is Y or F;

(vii) X10 is D, E or A; and

(viii) X11 is any amino acid.

6. The protein of claim 1 that is not immunogenic in humans.

7. The protein of claim 1 that is a full length IgG antibody.

8. The protein of claim 1 that is an antigen binding fragment of an antibody, and does not include an Fc domain.

9. The protein claim 1 that has at least a 20-fold preference for binding to activated LFA-1 relative to inactivated LFA-1.

10. A protein comprising an immunoglobulin heavy chain (HC) variable domain sequence and an immunoglobulin light chain (LC) variable domain sequence, wherein

(i) the HC variable domain sequence and the LC variable domain sequence form an antigen binding site that binds to an activated conformation of LFA-1 ("aLFA-1");

(ii) the protein inhibits ICAM-1 binding to LFA-1 on human peripheral blood mononuclear cells with an IC_{50} of less than 5 nM.

11. A pharmaceutical composition that comprises the protein according to any of claims 1-10 and a pharmaceutically acceptable salt.